Gilead Sciences Inc. share price logo

Gilead Sciences Inc. Share Price

NASDAQ: GILD

Large Cap

$148.94

+5.17

(+3.60%)

as on

Gilead Sciences Inc. Stock Performance

as on February 28, 2026 at 7:59 am IST

  • Day's Low

    Day's High

    $143.37
    $150.00
    downward going graph

    3.74%

    Downside

    0.71%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $93.37
    $157.29
    downward going graph

    37.31%

    Downside

    5.61%

    Upside

    downward going graph

Gilead Sciences Inc. share price movements today

Previous Close
$143.77
Open
$143.66
Volume
6.2M
Day's Low - High
$143.37 - $150.00
52 Week Low - High
$93.37 - $157.29

Gilead Sciences Inc. Historical Returns

1 Month Return
+ 6.61 %
3 Month Return
+ 18.36 %
1 Year Return
+ 30.3 %
3 Year Return
+ 84.96 %
5 Year Return
+ 142.59 %

Gilead Sciences Inc. Stock Fundamentals & Key Indicators

Check Gilead Sciences Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$178.4B

EPS (TTM)

8.683

Dividend Yield

3.74%

Quarterly Earnings Growth YOY

0.23%

PE Ratio (TTM)

21.17

Industry PE ratio

17.325641025641026

PEG Ratio

0.281

EBITDA

14.6B

Revenue (TTM)

29.4B

Profit Margin

28.90%

Return On Equity TTM

40.66%

Gilead Sciences Inc. Stock Valuation

Track how Gilead Sciences Inc. P/E has moved over time to understand its valuation trends.

Gilead Sciences Inc. in the last 5 years

  • Overview

  • Trends

Lowest (7.99x)

September 30, 2021

Industry (17.33x)

February 28, 2026

Today (21.17x)

February 28, 2026

Highest (19.53x)

December 31, 2024

LowHigh

Today’s Price to Earnings Ratio: 21.17x

Gilead Sciences Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Gilead Sciences Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Gilead Sciences Inc. image
Gilead Sciences Inc.
HOLD$178.4B142.59%21.1728.90%
Eli Lilly And Company image
Eli Lilly And Company
BUY$964.1B413.44%44.4431.67%
ASTRAZENECA PLC image
ASTRAZENECA PLC
BUY$316.2B330.86%31.1417.41%
Johnson & Johnson image
Johnson & Johnson
BUY$586.7B56.78%22.0728.46%
Abbvie Inc image
Abbvie Inc
BUY$397.3B115.41%95.216.91%
See all

Stock Returns calculator for Gilead Sciences Inc. Stock including INR - Dollar returns

The Gilead Sciences Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Gilead Sciences Inc. investment value today

Current value as on today

₹1,34,359

Returns

₹34,359

(+34.36%)

Returns from Gilead Sciences Inc. Stock

₹30,295 (+30.29%)

Dollar Returns*

₹4,064 (+4.06%)

Analyst Recommendation on Gilead Sciences Inc. Stock

Based on 38 analysts

HOLD

47.37%

Buy

52.63%

Hold

0.00%

Sell

Based on 38 analysts, 52.63% of analysts recommend a 'HOLD' rating for Gilead Sciences Inc.. Average target price of $156.59

Gilead Sciences Inc. Share Price Target

Get share price movements and forecasts by analysts on Gilead Sciences Inc..

What analysts predicted

4.89%UPSIDE

Target Price

$156.59

Current Price

$148.94

Analyzed by

38 Analysts

Target

$156.59

Gilead Sciences Inc. target price $156.59, a slight upside of 4.89% compared to current price of $148.94. According to 38 analysts rating.

Gilead Sciences Inc. Stock’s Investor Sentiment and Interest

Search interest for Gilead Sciences Inc. Stock has increased by 74% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:74% versus previous 30 day period

Gilead Sciences Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
7,050
7,114
6,686
6,953
7,545
7,569
6,667
7,081
7,769
7,925
Gross Profit
5,485
5,024
5,134
5,409
5,971
5,988
5,127
5,580
6,200
6,882
Operating Income
2,623
1,612
-4,322
2,644
888
2,452
2,237
2,474
3,327
2,964
EBITDA
3,234
2,593
-3,542
2,984
1,884
3,109
2,605
3,374
4,583
2,333
Interest Expense
232
252
254
237
238
249
260
254
256
255
Depreciation
684
688
690
694
690
693
696
691
686
687
Income Before Tax
2,318
1,653
-4,486
2,053
956
2,167
1,649
2,429
3,641
2,078
Income Tax Expense
146
237
-315
438
-297
385
334
468
589
-105
Net Income
2,180
1,429
-4,170
1,614
1,253
1,783
1,315
1,960
3,052
2,183
Net Profit Margin
30.92%
20.09%
-62.37%
23.21%
16.61%
23.56%
19.72%
27.68%
39.28%
27.55%

Gilead Sciences Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
30,390
26,107
22,127
22,449
24,689
27,305
27,281
27,116
28,754
29,443
Gross Profit
26,129
21,736
17,274
17,774
20,117
20,704
21,624
27,116
22,503
25,523
Operating Income
17,633
14,124
8,200
4,287
4,071
9,918
7,330
7,605
1,662
11,817
EBITDA
19,219
15,933
10,305
7,559
4,133
11,329
8,852
7,605
4,434
10,820
Interest Expense
964
1,118
1,077
995
984
1,001
935
944
977
1,024
Depreciation
-
1,286
1,429
1,404
1,480
2,050
2,103
2,533
2,767
2,760
Income Before Tax
17,097
13,529
7,799
5,160
1,669
8,278
5,814
6,859
690
9,796
Income Tax Expense
3,609
8,885
2,339
-204
1,580
2,077
1,248
-1,247
211
1,286
Net Income
13,501
4,628
5,455
5,386
123
6,225
4,592
5,665
480
8,510
Net Profit Margin
44.43%
17.73%
24.65%
23.99%
0.50%
22.80%
16.83%
20.89%
1.67%
28.90%

Gilead Sciences Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
1,417
-4,170
1,614
1,253
1,783
1,315
1,960
3,052
2,183
Operating Cash Flow
2,169
2,219
1,325
4,309
2,975
1,757
827
4,108
3,326
Investing Cash Flow
-727
-2,207
-307
-710
-225
-415
-2,116
-427
-1,835
Financing Cash Flow
-1,099
-1,361
-2,953
-1,379
2,260
-3,426
-1,567
-1,489
-1,263
Change in Cash
380
-1,367
-1,946
2,265
4,954
-2,065
-2,782
2,186
234

Gilead Sciences Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
4,644
5,460
5,364
89
6,201
4,566
5,665
480
8,510
Operating Cash Flow
11,898
8,400
9,144
8,168
11,384
9,072
8,006
10,828
10,019
Investing Cash Flow
-16,069
14,355
-7,817
-14,615
-3,131
-2,466
-2,265
-3,449
-4,793
Financing Cash Flow
3,393
-12,318
-7,634
770
-8,877
-6,469
-5,125
-3,433
-7,745
Change in Cash
-641
10,352
-6,309
-5,634
-659
74
673
3,906
-2,427

Mutual Funds that own Gilead Sciences Inc. Stock

Check out the Mutual Funds with significant holdings in Gilead Sciences Inc..

Global Institutional Holdings in Gilead Sciences Inc.

Funds
Holdings
T. Rowe Price Associates, Inc.
1.9%
Dimensional Fund Advisors, Inc.
0.82%
Wellington Management Company LLP
3.02%
Dodge & Cox
2.48%
Bank of America Corp
1.53%
See all

Gilead Sciences Inc. News & Key Events

  • img

    Today's Timeline - 24 February

    Tue, 01:32 PM

    -

    Gilead Sciences' price target increased by 11.73% to $159.01, reflecting bullish analyst sentiment.

    Wed, 00:07 AM

    -

    Gilead to acquire Arcellx for $7.8 billion, enhancing its cell therapy portfolio.

    Wed, 02:56 AM

    -

    Gilead's 2025 10-K report shows significant financial growth and strategic initiatives despite competitive challenges.

Insights on Gilead Sciences Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Gilead Sciences Inc. has shown consistent revenue growth over the last four quarters. The company's revenue rose from $6.66 billion to $7.92 billion, resulting in an average increase of 5.6% each quarter.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, GILD stock has moved up by 18.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, ASTRAZENECA PLC has given 173.5% return, outperforming this stock by 143.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Eli Lilly And Company has given 219.8% return, outperforming this stock by 134.8%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Gilead Sciences Inc. has experienced a decline in net profit over the last two quarters. The company's net profit fell from $3.05 billion to $2.18 billion, representing an average decrease of 28.5% per quarter.

About Gilead Sciences Inc.

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
OrganisationGilead Sciences Inc.
Headquarters333 Lakeside Drive, Foster City, CA, United States, 94404
IndustryHealth Technology
CEOMs. Johanna Mercier
E-voting on sharesClick here to vote

Key Management of Gilead Sciences Inc.

Name

Title

Ms. Cindy Perettie

Executive Vice President of Kite

Dr. Linda Slanec Higgins Ph.D.

Senior Vice President of Research, Innovation & Portfolio

Mr. Bernard M. Fine M.D., Ph.D.

VP of Oncology & Franchise Head of Early Development

Dr. Stacey Y. Ma Ph.D.

Executive VP of Pharmaceutical Development & Manufacturing

Dr. Flavius Martin M.D.

Executive Vice President of Research

Ms. Janet Dorling

Senior Vice President of Intercontinental Region & Global Patient Solutions

Dr. Dietmar P. Berger M.D., Ph.D.

Chief Medical Officer

Ms. Johanna Mercier

Chief Commercial & Corporate Affairs Officer

Ms. Jacquie Ross C.F.A.

Senior Vice President of Treasury and Investor Relations

Ms. Keeley Wettan

Executive VP and General Counsel of Legal & Compliance

FAQs

What is Gilead Sciences Inc. share price today?

Gilead Sciences Inc. share price today is $148.94 as on at the close of the market. Gilead Sciences Inc. share today touched a day high of $150 and a low of $143.37.

What is the 52 week high and 52 week low for Gilead Sciences Inc. share?

Gilead Sciences Inc. share touched a 52 week high of $157.29 on and a 52 week low of $93.37 on . Gilead Sciences Inc. stock price today i.e. is closed at $148.94,which is 5.31% down from its 52 week high and 59.52% up from its 52 week low.

What is Gilead Sciences Inc.'s market capitalisation today?

Gilead Sciences Inc. market capitalisation is $0.18T as on .

How to invest in Gilead Sciences Inc. Stock (GILD) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Gilead Sciences Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Gilead Sciences Inc. Shares that will get you 0.0101 shares as per Gilead Sciences Inc. share price of $148.94 per share as on February 28, 2026 at 2:29 am IST.

What is the minimum amount required to buy Gilead Sciences Inc. Stock (GILD) from India?

Indian investors can start investing in Gilead Sciences Inc. (GILD) shares with as little as ₹91.026 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹910.26 in Gilead Sciences Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Gilead Sciences Inc. share’s latest price of $148.94 as on February 28, 2026 at 2:29 am IST, you will get 0.0671 shares of Gilead Sciences Inc.. Learn more about fractional shares .

What are the returns that Gilead Sciences Inc. has given to Indian investors in the last 5 years?

Gilead Sciences Inc. stock has given 142.59% share price returns and 23.83% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?